Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering James PhillipsFebruary 9, 2023
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 James PhillipsFebruary 7, 2023
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders James PhillipsJanuary 31, 2023
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 James PhillipsJanuary 10, 2023
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model James PhillipsNovember 18, 2022
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease James PhillipsOctober 25, 2022
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement James PhillipsOctober 6, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress James PhillipsAugust 12, 2022
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering James PhillipsJuly 29, 2022
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering James PhillipsJuly 26, 2022
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJuly 22, 2022
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJuly 14, 2022
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsJune 13, 2022
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis James PhillipsMay 23, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress James PhillipsMay 16, 2022
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update James PhillipsApril 6, 2022
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection James PhillipsMarch 30, 2022
Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection James PhillipsMarch 24, 2022
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC James PhillipsMarch 22, 2022
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx‑99 for the Prevention of H3N2 Influenza Infection James PhillipsMarch 15, 2022
